Why it's happening:
Through this deal, Celgene lands itself ozanimod, a drug many believe could end up becoming the best-in-class oral therapy for treating relapsing multiple sclerosis.
In mid stage trials, ozanimod delivered impressive efficacy, but even more importantly, it did so with placebo-like safety -- an advantage that could prove critical to winning share in this $17 billion (and growing) market. Results from late stage trials that could support an FDA filing should be available in 2017.
If results are positive and an approval follows, it remains to be seen just how much of the MS market Celgene could eventually capture -- but it could total in the billions of dollars. Currently, the two top selling oral MS therapies are Biogen 's Tecfidera and Novartis ' Gilenya, and those drugs delivered annualized sales of $2.4 billion and $3.2 billion in the first quarter, respectively. Because ozanimod could have an arguably better safety profile than both of these drugs, its revenue opportunity may be bigger.
Additionally, ozanimod may be able to eventually carve out sales in other indications too. Studies are under way evaluating its potential as a treatment for ulcerative colitis and Crohn's disease, two indications that Celgene's already targeting with its Otezla and GED-0301. Overall, ozanimod's potential in MS and irritable bowel diseases has Celgene estimating that ozanimod's peak sales could be between $4 billion and $6 billion annually.
If so, then Celgene believes that ongoing growth in its existing drugs alongside upside from ozanimod will lead to revenue of at least $21 billion and adjusted EPS of at least $13 in 2020. That guidance, which is above the $20 billion in sales and $12.50 in adjusted EPS forecast in January, could mean that Celgene's shares aren't done heading higher.
This $19 trillion industry could destroy the Internet
One bleeding-edge technology is about to put the World Wide Web to bed. And if you act quickly, you could be among the savvy investors who enjoy the profits from this stunning change. Experts are calling it the single largest business opportunity in the history of capitalism... The Economist is calling it "transformative"... But you'll probably just call it "how I made my millions." Don't be too late to the party -- click here for one stock to own when the Web goes dark.
The article Why Shares in Celgene Corp Are Rocketing Higher Today originally appeared on Fool.com.
Todd Campbell owns shares of Celgene. Todd owns the equity research firm E.B. Capital Markets, LLC. E.B. Capital's clients may have positions in the companies mentioned. The Motley Fool recommends Celgene. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
Copyright © 1995 - 2015 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .